US2020397850A1PendingUtilityA1

Methods and compositions for the prevention and treatment neuropathy

70
Assignee: STEALTH BIOTHERAPEUTICS CORPPriority: Mar 30, 2012Filed: Apr 7, 2020Published: Dec 24, 2020
Est. expiryMar 30, 2032(~5.7 yrs left)· nominal 20-yr term from priority
Inventors:D. Travis Wilson
A61K 31/337A61K 31/4245A61P 43/00A61P 25/04A61P 39/02A61K 31/4748A61P 35/00A61K 31/137A61P 25/02A61K 31/7042A61K 31/185A61K 31/55A61K 38/07A61K 38/08A61K 33/243A61K 31/366
70
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The disclosure relates to methods for treating a subject suffering from hyperalgesia caused by drug-induced neuropathy by administering to the subject an effective amount of an aromatic-cationic peptide. The disclosure also relates to methods for protecting a subject from hyperalgesia caused by drug-induced neuropathy by administering an effective amount of an aromatic-cationic peptide to a subject at risk for developing the condition.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method for treating peripheral neuropathy or hyperalgesia in a subject in need thereof, comprising administering to the subject an effective amount of a peptide having the formula D-Arg-2′6′-dimethyltyrosine-Lys-Phe-NH 2 . 
     
     
         2 . The method of  claim 1 , wherein the peripheral neuropathy or hyperalgesia is drug-induced. 
     
     
         3 . The method of  claim 2 , wherein the drug is a chemotherapeutic agent. 
     
     
         4 . The method of  claim 3 , wherein the chemotherapeutic agent is procarbazine, nitrofurazone, podophyllum, mustine, ethoglucid, cisplatin, suramin, paclitaxel, chlorambucil, altretamine, carboplatin, cytarabine, docetaxel, dacarbazine, etoposide, ifosfamide with mesna, fludarabine, tamoxifen, teniposide, thioguanine, or vincristine. 
     
     
         5 . The method of  claim 3 , wherein the chemotherapeutic agent is vincristine. 
     
     
         6 . The method of  claim 2 , wherein the peptide is administered simultaneous with the drug. 
     
     
         7 . The method of  claim 2 , wherein the peptide is administered subsequent to the drug. 
     
     
         8 . The method of  claim 1 , wherein the peripheral neuropathy causes hyperalgesia. 
     
     
         9 . The method of  claim 1 , wherein the subject is a human. 
     
     
         10 . The method of  claim 1 , wherein the peptide is administered intravenously, orally, subcutaneously, transdermally, intraperitoneally, intrathecally intramuscularly, intranasally, bucally, sublingually, translingually, or topically. 
     
     
         11 . A method for preventing hyperalgesia in a subject in need thereof, comprising administering to the subject an effective amount of a peptide having the formula D-Arg-2′6′-dimethyltyrosine-Lys-Phe-NH 2 . 
     
     
         12 . The method of  claim 11 , wherein the hyperalgesia is drug-induced. 
     
     
         13 . The method of  claim 12 , wherein the drug is a chemotherapeutic agent. 
     
     
         14 . The method of  claim 13 , wherein the chemotherapeutic agent is procarbazine, nitrofurazone, podophyllum, mustine, ethoglucid, cisplatin, suramin, paclitaxel, chlorambucil, altretamine, carboplatin, cytarabine, docetaxel, dacarbazine, etoposide, ifosfamide with mesna, fludarabine, tamoxifen, teniposide, thioguanine, or vincristine. 
     
     
         15 . The method of  claim 13 , wherein the chemotherapeutic agent is vincristine. 
     
     
         16 . The method of  claim 12 , wherein the peptide is administered simultaneous with the drug. 
     
     
         17 . The method of  claim 12 , wherein the peptide is administered subsequent to the drug. 
     
     
         18 . The method of  claim 11 , wherein the peptide is administered prior the onset of hyperalgesia. 
     
     
         19 . The method of  claim 11 , wherein the subject is a human. 
     
     
         20 . The method of  claim 11 , wherein the peptide is administered intravenously, orally, subcutaneously, transdermally, intraperitoneally, intrathecally intramuscularly, intranasally, bucally, sublingually, translingually, or topically. 
     
     
         21 . A composition for treating or preventing hyperalgesia in a subject in need thereof, comprising an effective amount of a peptide having the formula D-Arg-2′6′-dimethyltyrosine-Lys-Phe-NH 2 . 
     
     
         22 . The composition of  claim 21 , wherein the hyperalgesia is drug-induced. 
     
     
         23 . The composition of  claim 22 , wherein the drug is a chemotherapeutic agent. 
     
     
         24 . The composition of  claim 23 , wherein the chemotherapeutic agent is procarbazine, nitrofurazone, podophyllum, mustine, ethoglucid, cisplatin, suramin, paclitaxel, chlorambucil, altretamine, carboplatin, cytarabine, docetaxel, dacarbazine, etoposide, ifosfamide with mesna, fludarabine, tamoxifen, teniposide, thioguanine, or vincristine. 
     
     
         25 . The composition of  claim 22 , wherein the chemotherapeutic agent is vincristine. 
     
     
         26 . The composition of  claim 22 , wherein the peptide is administered simultaneous with the drug. 
     
     
         27 . The composition of  claim 22 , wherein the peptide is administered subsequent to the drug. 
     
     
         28 . The composition of  claim 21 , wherein the peptide is administered prior the onset of hyperalgesia. 
     
     
         29 . The composition of  claim 21 , wherein the subject is a human. 
     
     
         30 . The composition of  claim 21 , wherein the peptide is administered intravenously, orally, subcutaneously, transdermally, intraperitoneally, intrathecally intramuscularly, intranasally, bucally, sublingually, translingually, or topically.

Join the waitlist — get patent alerts

Track US2020397850A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.